Clinical trial
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed…
NCT00097929 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00097929 |
|---|---|
| Title | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) |
| Official title | A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Lymphoma |
| Intervention type | Drug |
| Interventions | MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months |
| Enrollment | 18 |
| Start date | May 1, 2005 |
| Primary completion | Jul 31, 2006 |
| Completion | Jul 31, 2006 |
| First posted | Dec 2, 2004 |
| Last update posted | Apr 7, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: